Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pharnext Presents a Business Update Webcast on May 20th, 2020

eqs_en 
0 0 14.05.20
Pharnext Presents a Business Update Webcast on May 20th, 2020
 

Pharnext
Pharnext Presents a Business Update Webcast on May 20th, 2020

14-May-2020 / 18:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Pharnext Presents a Business Update Webcast
on May 20th, 2020

PARIS, France, 6:00 pm, May 14, 2020 (CET) - Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today confirmed the organization of a webcast to update on its current activities on May 20th, 2020 at 6:00 pm (CET).

During this webcast, David Horn Solomon, Chief Executive Officer, will provide a business update and overview of Pharnext.

Attendees can participate by weblink: https://channel.royalcast.com/webcast/pharnext/20200520_1/
or connect by phone using the following coordinates:

Confirmation Code: Pharnext

Dials-in:
- USA: +1 212 999 6659
- France: +33 (0) 1 7099 4740
- UK: +44 (0) 20 3003 2666


About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY(TM). Pharnext identifies and develops synergic combinations of drugs called PLEODRUG(TM). The Company was founded by renowned scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.

Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).














Contacts
Pharnext
David Solomon
Chief Executive Officer
[email protected]m
+33 (0)1 41 09 22 30 		     
Media Relations (Europe)
Ulysse Communication
Bruno Arabian
+33 (0)6 87 88 47 26
barabian@ulysse-communication.com
Pierre-Louis Germain
+33 (0)6 64 79 97 51
[email protected]
+33 (0)1 81 70 96 30 		Financial Communication (France)
Actifin
Stéphane Ruiz
[email protected]
+33 (0)1 56 88 11 15 		Investors Relations (U.S.)
Stern Investor Relations, Inc.
Jane Urheim
jane.urheim@sternir.com
+1 212 362 1200
           

 
Regulatory filing PDF file

Document title: Pharnext Presents a Business Update Webcast on May 20th, 2020
Document: https://eqs-cockpit.com/c/fncls.ssp?u=WJAUTBDXSI

1045795  14-May-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1045795&application_name=news&site_id=sharewise

Pharnext S.A. Stock

€0.000
-

The community is currently still undecided about Pharnext S.A. with 1 Buy predictions and 0 Sell predictions.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!